COVID-19 and Senotherapeutics: Any Role for the Naturally-occurring Dipeptide Carnosine?

Alan R. Hipkiss*

Aston Research Centre for Healthy Ageing (ARCHA), Aston University, Birmingham, B4 7ET, UK

[Received May 15, 2020; Revised May 17, 2020; Accepted May 18, 2020]

ABSTRACT: It is suggested that the non-toxic dipeptide carnosine (beta-alanyl-L-histidine) should be examined as a potential protective agent against COVID-19 infection and inflammatory consequences especially in the elderly. Carnosine is an effective anti-inflammatory agent which can also inhibit CD26 and ACE2 activity. It is also suggested that nasal administration would direct the peptide directly to the lungs and escape the attention of serum carnosinase.

Key words: carnosine, acetyl-carnosine, inflammation, virus, olfaction, lungs, aging.

It has become clear that, compared to the young, elderly humans are especially susceptible to fatal infection by COVID-19, most likely due, it is thought, to pre-existing, age-related, underlying conditions. Consequently, a number of recent publications [1,2,3,4] have discussed how the processes of ageing might enhance the impact of the COVID-19 virus upon human physiology. Furthermore, it has been proposed that agents which suppress ageing onset and/or development, should be explored for mitigation of COVID-19 toxicity and mortality in the elderly [1,3,4]. Indeed, a search for effective senotherapeutics has considered a range of possible anti-aging agents and the mechanistic routes that might ameliorate age-related change [3]. It is proposed here that the naturally-occurring dipeptide carnosine (beta-alanyl-L-histidine) should also be considered as a potential senotherapeutic which may help to suppress COVID-19 toxicity.

Carnosine, aging and COVID-19

There is evidence, first obtained more than 25 years ago, that carnosine delays senescence, extends lifespan and even rejuvenates cultured human lung fibroblasts [5]. Subsequent studies revealed that carnosine (i) can delay ageing and/or related phenomena in some animal models [6-10], (ii) possesses anti-oxidant and anti-glycating activities [11-15], (iii) possesses anti-inflammatory properties [16-20], (iv) is protective towards lung injury [21-23], (v) can decrease the infectivity of RNA viruses Zika, Denge [24] and influenza [25], (vi) is an inhibitor of CD26 (also known and dipeptidyl peptidase IV (DPP4) [26,27] and ACE-2 (angiotensin converting enzyme 2) [28,29], i.e. the cell receptors to which COVID-19 attaches to ensure infection [30,31], (vii) can complex with zinc ions to form polaprezinc [32]; it has been reported that zinc ions can inhibit COVID-19 RNA polymerase thus suppressing viral replication [33].

*Correspondence should be addressed to: Dr. Alan R. Hipkiss, Aston Research Centre for Healthy Ageing (ARCHA), Aston University, Birmingham, B4 7ET, UK. Email: alanandjill@lineone.net

Copyright: © 2020 Hipkiss AR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Carnosine and blood

Another role for carnosine could include beneficial effects in blood. Recent findings suggest that COVID-19 infection can promote in some patients a hypercoagulatory state, which is associated increased mortality [34]. The glycolytic by-product methylglyoxal (MG) is generated in increased amounts in type-2 diabetics, especially in erythrocytes following high glycemic-index diets [35]. MG is responsible for much post-synthetic protein glycation in diabetics, including the anti-coagulants anti-thrombin III [36] and plasminogen [37], resulting in a hyper-coagulatory state. Given that carnosine can inhibit protein glycation and possibly scavenge MG, the dipeptide might suppress the MG-induced anti-coagulant modification.

Recent studies have shown that carnosine and acetyl-carnosine are present in human blood; carnosine is present in erythrocytes and acetyl-carnosine is mostly in serum; erythrocytes normally contain carnosine and 10-fold less acetyl-carnosine, while the situation is reversed in serum where acetyl-carnosine is the predominant form. Importantly, these levels decline in elderly humans [38] and low levels of acetyl-carnosine are associated with enhanced frailty [39]. Low carnosine levels have also been detected in blood from patients suffering from age-related macular degeneration [40].

It is perhaps interesting to note that carnosine synthesis may be affected by trauma, even in the distant past, which could influence an individual’s blood carnosine and acetyl-carnosine levels. In adults subjected to childhood trauma, the carnosine synthase gene showed increased methylation, which would decrease carnosine synthesis [41]. Childhood trauma has been linked to psychopathology, accelerated aging-related DNA methylation [42] and schizophrenia [43]. Furthermore, erythrocytes from schizophrenics show evidence of increased aging-related protein glycation [44], while dietary carnosine supplementation has been shown to produce beneficial effects in schizophrenics [45], possibly due, in part, to carnosine’s anti-glycating activity [11,12].

Carnosine as a possible senotherapeutic

All the factors outlined above, lead one to suggest that carnosine should be considered as a possible senotherapeutic, acting either prophylactically by helping to suppress the development of an increasingly frail senescent phenotype and/or therapeutically by interfering with COVID-19 infection (given its reported effects on DPP4 and ACE2). Furthermore, carnosine’s anti-inflammatory effects may help suppress post-infection inflammatory response and fibrosis [46]. It may also be significant that loss of a sense of smell frequently accompanies COVID-19 infection [47], and that the olfactory lobe is normally enriched with carnosine [48]. Consequently, it is suggested that the dipeptide is worth exploring for suppression of COVID-19 toxicity in aged humans, especially in subjects already possessing age-related dysfunction.

As noted above, a decreased serum level of acetyl-carnosine (unsusceptible to hydrolysis by serum carnosinase) has recently been noted as an indicator of frailty in elderly humans [39], thus it may be informative if blood levels of acetyl-carnosine and carnosine could be determined in COVID-19 infected patients.

There have been a number of studies in which dietary supplementation with carnosine has been explored. Beneficial effects have been observed in schizophrenics [45], Gulf War veterans [49], obese humans [50], diabetics [51], elderly human verbal memory [52], autistic children [53,54] and patients with chronic heart failure [55]. Unfortunately, a major problem with oral administration of carnosine is the presence of carnosinase in serum which will destroy the peptide; indeed high carnosinase activity can limit the efficacy of orally administered carnosine towards chronic kidney disease [56]. An alternative approach would be to use nasal delivery, either as an aerosol or in powder form, thus eliminating the serum carnosinase problem and targeting carnosine directly to the lungs. Hopefully this would suppress COVID-19 infectivity via the dipeptide’s inhibitory effects on both ACE2 and MPP4. Moreover, carnosine’s well-recognised anti-inflammatory activity could suppress any excessive inflammatory response following infection. Such an approach may be especially important in frail subjects, exhibiting low levels of acetyl-carnosine (resistant to carnosinase attack). The precise relationship between these two molecules remains to be revealed; for example, is red cell carnosine a precursor of acetyl-carnosine which is then released from the cell?

Conclusion.

Carnosine has previously been described as enigmatic [57], and the dipeptide has been shown to exert a variety of effects at biochemical and physiological levels resulting in a large number of possible biological functions [58]. Indeed, as aging is multifactorial, any putative anti-aging agent might be expected to be pluripotent in its actions [59]. Thus, carnosine’s cumulative multifunctional activities could result in a physiologically beneficial outcome in COVID-19 infected aged humans. In order to decrease virus-associated mortality, it is suggested that elderly subjects with low blood carnosine and acetyl-carnosine levels should receive exogenous carnosine, administered nasally.
Conflict of interest

The author has no conflict of interest.

References

[1] Malavolta M, Giacconi R, Brunetti D, Provinciali M, Maggi F (2020). Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2. Emergency and Similar Future Global Health Threats. Cells, 9(4):E909.

[2] Lau G, Sinclair D (2020). Biomarkers of biological age as predictors of COVID-19 disease severity. Aging, in press.

[3] Zhavoronkov A (2020). Geroprotection and Senoremediation Strategies to Reduce the Comorbidity, Infection Rates, Severity, and Lethality in Gerophilic and Gerolavic Infections. Aging, 12:6492-6510.

[4] Promislow DEL (2020). A geroscience perspective on COVID-19 mortality. J Gerontol A Biol Sci Med Sci, in press.

[5] McFarland GA, Holliday R (1994). Retardation of the senescence of cultured diploid fibroblasts by carnosine. Exp Cell Res, 212(2):167-75.

[6] Stvolinsky S, Antipin M, Meguro K, Sato T, Abe H, Boldyreva AA (2010). Effect of carnosine and its Trolox-modified derivatives on life span of Drosophila melanogaster. Rejuvenation Res, 13(4):453-7.

[7] Yuneva AO, Kramarengo GG, Vetreshchak TV, Gallant S, Boldyreva AA (2002). Effect of carnosine on Drosophila melanogaster lifespan. Bull Exp Biol Med, 133(6):559-61.

[8] Larroque-Cardoso P, Camaré C, Nadal-Wollbold F, Grazide MH, Pucelle M, Garoby-Salom S, et al. (2015). Elastin Modification by 4-Hydroxynonenal in Hairless Mice Exposed to UV-A: Role in Photoaging and Actinic Elastosis. J Invest Dermatol, 135(7):1873-1881.

[9] Corona C, Frazzini V, Silvestri E, Lattanzio R, La Sorda R, Piantelli M, et al. (2011). Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice. PLoS One, 6(3):e17971.

[10] Gallant S, Semyonova M, Yuneva M (2000). Carnosine as a potential anti-senescence drug. Biochemistry, 65(7):866-8.

[11] Aydin AF, Bingül İ, Küçükgergin C, Doğan-Ekici I, Doğru Abbassoğlu S, Uysal M (2017). Carnosine decreased oxidation and glycation products in serum and liver of high-fat diet and low-dose streptozotocin-induced diabetic rats. Int J Exp Pathol, 98(5):278-288.

[12] Bingül İ, Yılmaz Z, Aydin AF, Çoban J, Doğru-Abbassoğlu S, Uysal M. (2017). Antiglycation and antioxidant efficiency of carnosine in the plasma and liver of aged rats. Geriatr Gerontol Int, 17(12):2610-2614.

[13] Xie Z, Baba SP, Sweeney BR, Barski OA (2013). Detoxification of aldehydes by histidine-containing dipeptides: from chemistry to clinical implications. Chem Biol Interact, 202(1-3):288-97

[14] Seidler NW, Yeargas GS (2002). Effects of thermal denaturation on protein glycation. Life Sci, 70(15):1789-99

[15] Hipkiss AR, Brownson C (2000). Carnosine reacts with protein carbonyl groups: another possible role for the anti-ageing peptide? Biogerontology, 1(3):217-23.

[16] Qu F, Xu W, Deng Z, Xie Y, Tang J, Chen Z, et al. (2020). Fish c-Jun N-Terminal Kinase (JNK) Pathway Is Involved in Bacterial MDP-Induced Intestinal Inflammation. Front Immunol, 11:459.

[17] Impellizzeri D, Siracusa R, Cordaro M, Peritore AF, Gugliandolo E, D’Amico R, et al. (2020). Protective effect of a new hyaluronic acid -carnosine conjugate on the modulation of the inflammatory response in mice subjected to collagen-induced arthritis. Biomed Pharmacother, 125:110023.

[18] Fresta CG, Fidilio A, Lazzarino G, Musso N, Grasso M, Merlo S, et al. (2020). Modulation of Pro-Oxidant and Pro-Inflammatory Activities of M1 Macrophages by the Natural Dipeptide Carnosine. Int J Mol Sci, 21(3):776.

[19] Fadda LM, Ali HM, Mohamed AM, Hagar H (2019). Prophylactic administration of carnosine and melatonin abates the incidence of apoptosis, inflammation, and DNA damage induced by titanium dioxide nanoparticles in rat livers. Environ Sci Pollut Res Int, in press.

[20] Caruso G, Fresta CG, Musso N, Giambirtone M, Grasso M, Spampinato SF, et al. (2019). Carnosine Prevents Aβ-Induced Oxidative Stress and Inflammation in Microglial Cells: A Key Role of TGF-β1. Cells, 8:64.

[21] Tanaka KI, Kawahara M (2019). Carnosine and Lung Disease. Curr Med Chem, in press.

[22] Sun C, Wu Q, Zhang X, He Q, Zhao H (2017). Mechanistic Evaluation of the Protective Effect of Carnosine on Acute Lung Injury in Sepsis Rats. Pharmaco, 100(5-6):292-300.

[23] Tanaka KI, Sugizaki T, Kanda Y, Tamura F, Niino T, Kawahara M (2017). Preventive Effects of Carnosine on Lipopolysaccharide-induced Lung Injury. Sci Rep, 7:42813.

[24] Rothen HA, Abdulrahman AY, Khazali AS, Nor Rashid N, Chong TT, Yusof R (2019). Carnosine exhibits significant antiviral activity against Dengue and Zika virus. J Pept Sci, 25(8):e3196.

[25] Xu T, Wang C, Zhang R, Xu M, Liu B, Wei D, et al. (2015). Carnosine markedly ameliorates H9N2 swine influenza virus-induced acute lung injury. J Gen Virol, 96(10):2939-2950.

[26] Gallego M, Aristoy MC, Toldrá F (2014). Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham. Meat Sci, 96(2 Pt A):757-61

[27] Vahdatpour T, Nikhodachi A, Zakeri-Milani P, Mesgar-Abbasi M, Ahmadi-Asl N, Valizadeh H (2019). Leucine-glycine and carnosine dipeptides prevent diabetes induced by multiple low-doses of streptozotocin in an experimental model of adult mice. J Diabetes Investig, 10(5):1177-1188.

[28] Hou WC, Chen HJ, Lin YH (2003). Antioxidant peptides with Angiotensin converting enzyme inhibitory activities and applications for Angiotensin
converting enzyme purification. J Agric Food Chem, 51(6):1706-9.

[29] Kilis-Patrusinska K (2020). Carnosine and Kidney Diseases: What We Currently Know? Curr Med Chem, 27(11):1764-1781.

[30] Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD (2020). Covid-19 and co-morbidities: a role for Dipeptidyl Peptidase 4 (DPP4) in disease severity? J Diabetes, in press.

[31] Magrone T, Magrone M, Jirillo E (2020). Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective. Endocr Metab Immune Disord Drug Targets, in press.

[32] Hewlings S, Kalman D (2020). A Review of Zinc-L-Carnosine and Its Positive Effects on Oral Mucositis, Taste Disorders, and Gastrointestinal Disorders. Nutrients, 12(3):665.

[33] Skalny AV, Rink L, Ajsvakova OP, Aschner M, Griskenko VA, Alekseenko SI, et al. (2020). Zinc and respiratory tract infections: Perspectives for COVID-19 (Review). Int J Mol Med, in press.

[34] Mucha SR, Dugar S, McCrae K, Joseph DE, Bartholomew J, Sacha G, et al. (2020). Coagulopathy in COVID-19. Cleve Clin J Med, in press.

[35] Hipkiss AR (2019). Aging, Alzheimer's Disease and Dysfunctional Glycolysis; Similar Effects of Too Much and Too Little. Aging Dis, 10(6):1328-1331.

[36] Jacobson R, Mignemi N, Rose K, O'Rear L, Sarilla S, Hamm HE, et al. (2014). The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent addition of antithrombin III. Thromb Res, 134(6):1350-7.

[37] Gugliucci A (2003). A practical method to study functional impairment of proteins by glycation and effects of inhibitors using current coagulation/ fibrinolysis reagent kits. Clin Biochem, 36: 155-158.

[38] Chaleckis R, Murakami I, Takada K, Kondoh H, Yanagida M (2016). Individual variability in human blood metabolites identifies age-related differences. Proc Natl Acad Sci U S A, 113(16):4252-9.

[39] Kameda M, Teruya T, Yanagida M, Kondoh H (2020). Frailty markers comprise blood metabolites involved in antioxidation, cognition, and mobility. Proc Natl Acad Sci U S A, in press.

[40] Chao de la Barca JM, Rondet-Courbis B, Ferré M, Muller J, Buisset A, Leruez S, Plubeau G, et al. (2020). A Plasma Metabolomic Profiling of Exudative Age-Related Macular Degeneration Showing Carnosine and Mitochondrial Deficiencies. J Clin Med, 9(3):631

[41] Marinova Z, Maercker A, Günlüblat E, Wojdacz TK, Walita S (2017). A pilot investigation on DNA methylation modifications associated with complex posttraumatic symptoms in elderly traumatized in childhood. BMC Res Notes, 10(1):752.

[42] McLaughlin KA, Colich NL, Rodman AM, Weissman DG (2020). Mechanisms linking childhood trauma exposure and psychopathology: a transdiagnostic model of risk and resilience. BMC Med, 18(1):96.

[43] Sallis HM, Croft J, Havdahl A, Jones HJ, Dunn EC, Davey Smith G, et al. (2020). Genetic liability to schizophrenia is associated with exposure to traumatic events in childhood. Psychol Med, 1-18.

[44] Ishida YI, Kayama T, Kibune Y, Nishimoto S, Koike S, Suzuki T, et al. (2017). Identification of an argpyrimidine-modified protein in human red blood cells from schizophrenic patients: A possible biomarker for diseases involving carbonyl stress. Biochem Biophys Res Commun, 493(1):573-577.

[45] Chengappa KN, Turkin SR, DeSanti S, Bowie CR, Brar JS, Schlicht PJ, et al. (2012). A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr Res, 142(1-3):145-52.

[46] Barbieri A, Sacchi A, Cimini E, Notari S, Grassi G, Tartaglia E, et al. (2020). An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19. Clin Infect Dis, in press.

[47] Izquierdo-Dominguez A, Rojas-Lechuga MJ, Mullol J, Allobid I (2020). Olfactory dysfunction in the COVID-19 outbreak. J Investig Allergol Clin Immunol, in press.

[48] Bonfanti L, Peretto P, De Marchis S, Fasolo A (1999). Carnosine-related dipeptides in the mammalian brain. Prog Neurobiol, 59(4):333-53.

[49] Baraniuk JN, El-Amin S, Corey R, Rayhan R, Timbol C (2013). Carnosine treatment for gulf war illness: a randomized controlled trial. Version 2. Glob J Health Sci, 4(5):69-81.

[50] Menon K, Marquina C, Liew D, Mousa A, de Courten B (2020). Histidine-containing dipeptides reduce central obesity and improve glycaemic outcomes: A systematic review and meta-analysis of randomized controlled trials. Obes Rev, 21(3):e12975.

[51] Menini S, Iacobini C, Fantauzzi CB, Pugliese G (2020). L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes. Curr Med Chem, 27(11):1744-1763.

[52] Masuoka N, Yoshimine C, Hori M, Tanaka M, Asada T, Abe K et al. (2019). Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4. Nutrients, 11(7):1626.

[53] Chez MG, Buchanan CP, Aimonovitch MC, Becker M, Schaefer K, Black C, et al. (2002). Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol, 17(11):833-7.

[54] Hajizadeh-Zaker R, Ghajar A, Mesgarpour B, Afarideh M, Mohammadi MR, Akhondzadeh S (2018). L-Carnosine as an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. J Child Adolesc Psychopharmacol, 28(1):74-81.

[55] Lombardi C, Carubelli V, Lazzarini V, Vizzardi E, Bordonali T, Ciccarese C, et al. (2015). Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. Nutrition, 31(1):72-8.
[56] Rodriguez-Niño A, Hauske SJ, Herold A, Qiu J, van den Born J, Bakker SJL, et al. (2019). Serum Carnosinase-1 and Albuminuria Rather than the CNDP1 Genotype Correlate with Urinary Carnosinase-1 in Diabetic and Nondiabetic Patients with Chronic Kidney Disease. J Diabetes Res, in press.

[57] Bauer K (2005). Carnosine and homocarnosine, the forgotten, enigmatic peptides of the brain. Neurochem Res, 30(10):1339-45.

[58] Chmielewska K, Dzierzbicka K, Inkielewicz-Stepniak I, Przybylowska M (2020). Therapeutic Potential of Carnosine and Its Derivatives in the Treatment of Human Diseases. Chem Res Toxicol, in press.

[59] Hipkiss AR, Baye E, de Courten B (2016). Carnosine and the processes of ageing. Maturitas, 93:28-33.